BioMarin Pharmaceutical

BioMarin Pharmaceutical (BMRN) is the lead sponsor of 25 active clinical trials listed on ClinicalTrials.gov^[5], including 5 Phase 3^[1], 10 Phase 2^[2], 5 Phase 1^[3], 1 Phase 4^[4].

Trial NCT03424018^[6] evaluates BMN 111 in Achondroplasia with a target enrollment of 119 participants. Trial NCT07073014^[7] evaluates Vosoritide in Hypochondroplasia with a target enrollment of 140 participants. Trial NCT06224907^[8] evaluates Valoctocogene roxaparvovec in Hemophilia A with a target enrollment of 6 participants.

BMRN has 11 Form 4 insider filings recorded at the SEC in the past 30 days^[9].